Healthy men test new allergy drug copycat in Early-Stage trial
NCT ID NCT07246252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new version of the allergy drug omalizumab (called CMAB007) against the original drug (Xolair) in 114 healthy Chinese men. The goal was to see how the body processes each drug, check for side effects, and compare immune responses. No treatment was given for any disease; the study simply gathered data to support future development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (HV) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Xuhui Central Hospital, Shanghai
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsing light on the scalp boost brain performance?
- Can heavy water reveal how the liver makes fat?
- Which bridge exercise fires up your muscles most? a study investigates
- A new molecule enters human testing: can ZE66-0205 prove safe?
- Reading DNA clues: a blood test that could sniff out lung cancer
- Blood flow restriction may change how hamstrings use oxygen during exercise